Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Rhea-AI Summary

Curanex Pharmaceuticals (Nasdaq: CURX) engaged Strategic Investor Relations, LLC on October 22, 2025 to strengthen investor communications and visibility. The firm will support outreach, refine messaging, and highlight Curanex’s botanical drug pipeline targeting ulcerative colitis, atopic dermatitis, and gouty arthritis.

The company's lead Ulcerative Colitis candidate is on track for an IND submission in 2026, and management emphasized regulatory compliance with the FDA and a development approach informed by over 30 years of clinical evidence in China.

Insights

Corporate Communications Strategist

Engagement of a specialist investor‑relations firm should modestly improve visibility but does not change clinical or financial fundamentals.

Curanex Pharmaceuticals has contracted Strategic Investor Relations, LLC to sharpen investor communications and outreach. The agreement focuses on explaining the company’s botanical drug approach, its multi‑indication pipeline for Ulcerative Colitis, Atopic Dermatitis, and Gouty Arthritis, and ongoing efforts to educate stakeholders about regulatory compliance and development milestones.

The practical business mechanism is communication amplification: a dedicated IR partner can increase access to analysts, improve messaging consistency, and surface the company’s stated milestone — an IND submission targeted for 2026. Risks and dependencies include the firm’s execution quality, market receptivity, and the fact that hiring IR does not alter clinical timelines or preclinical evidence.

Watch for concrete outputs from this engagement over the next 6–12 months: investor presentations, materially new disclosure about timelines or data, and measurable increases in investor engagement metrics. The near-term signal is informational; the substantive impact will depend on subsequent, verifiable clinical or financial disclosures.

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’s innovative pipeline and strategic initiatives.

With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the Company's progress and prospects. Strategic Investor Relations will assist Curanex in highlighting its botanical drug development approach, which encompasses high-efficacy botanical drugs with de-risked clinical pathways and its positioning in the rapidly expanding botanical drug market.

Curanex is advancing a robust pipeline targeting key inflammatory indications, including Ulcerative Colitis, Atopic Dermatitis, and Gouty Arthritis, leveraging decades of real-world use in China. The Company's lead botanical candidate for Ulcerative Colitis is on track for IND submission in 2026.

Curanex’s founders have established a strong foundation in botanical drug innovation, drawing on extensive preclinical data across multiple indications, with the focus on de-risked development, and with botanical programs informed by over 30 years of clinical evidence in China.They bring a commitment for Curanex to regulatory compliance with the FDA.

"Engaging with Strategic Investor Relations represents an important step towards strengthening our relations with current and prospective investors and better communicating our financial story and market opportunities," said Mr. Jun Liu, Chairman and Chief Executive Officer of Curanex Pharmaceuticals. "We are committed to enhancing our transparency and engagement with the investor community as we advance our drug development and deliver on our mission to transform inflammatory disease treatment. Together with the expertise of Strategic Investor Relations, we are confident in our ability to communicate our vision and clinical successes more effectively, driving enhanced shareholder value."

Mr. Matthew Abenante, President of Strategic Investor Relations, commented, “We are thrilled to partner with Curanex Pharmaceuticals, a trailblazer in dual-modality therapeutics for inflammatory diseases. Curanex's innovative botanical pipeline positions them uniquely for transformative growth. I am extremely excited about the future for Curanex as it continues to de-risk and advance its programs, ensuring the Company remains at the forefront of biopharmaceutical innovation.”

“We look forward to supporting their journey and are confident that Curanex's exciting future will deliver substantial value to their stakeholders," concluded Mr. Abenante.

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.

The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.

For more information, visit the Company’s website at www.curanexpharma.com.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

FAQ

What did Curanex (CURX) announce on October 22, 2025 regarding investor relations?

Curanex announced it engaged Strategic Investor Relations, LLC to enhance investor communications and visibility.

How will Strategic Investor Relations support Curanex (CURX) investors?

They will refine messaging, increase financial‑community visibility, and support engagement and investor education.

Which indications are Curanex (CURX) advancing in its botanical pipeline?

Curanex is advancing programs for ulcerative colitis, atopic dermatitis, and gouty arthritis.

When is Curanex (CURX) targeting an IND submission for its lead ulcerative colitis candidate?

The company said the lead ulcerative colitis candidate is on track for an IND submission in 2026.

What evidence does Curanex (CURX) cite to support its botanical drug approach?

Curanex cites over 30 years of clinical evidence in China and extensive preclinical data across multiple indications.

Does the Curanex (CURX) announcement include financial guidance or funding details?

No; the announcement focuses on investor relations engagement and clinical development updates, not financial guidance or funding amounts.